[Articles] A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial

Di |2023-12-08T00:30:01+01:00Dicembre 8th, 2023|Categorie: Coronavirus Lancet|

Treatment with SIM01 alleviates multiple symptoms of PACS. Our findings have implications on the management of PACS through gut microbiome modulation. Further studies are warranted to explore the beneficial effects of SIM01 in other chronic or post-inf...

[Articles] A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial

Di |2023-12-08T00:30:01+01:00Dicembre 8th, 2023|Categorie: Coronavirus Lancet|

Treatment with SIM01 alleviates multiple symptoms of PACS. Our findings have implications on the management of PACS through gut microbiome modulation. Further studies are warranted to explore the beneficial effects of SIM01 in other chronic or post-inf...

[Corrections] Correction to Lancet Infect Dis 2023; published online Nov 24. https://doi.org/10.1016/S1473-3099(23)00505-4

Di |2023-12-07T00:30:01+01:00Dicembre 7th, 2023|Categorie: Coronavirus Lancet|

Bandyopadhyay AS, Lopez Cavestany R, Blake IM, et al. Use of inactivated poliovirus vaccine for poliovirus outbreak response. Lancet Infect Dis 2023; published online Nov 24. https://doi.org/10.1016/S1473-3099(23)00505-4—In this Personal View, Ondrej M...

[Articles] Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial

Di |2023-12-05T00:30:04+01:00Dicembre 5th, 2023|Categorie: Coronavirus Lancet|

VAX-24 had a safety profile similar to PCV20 at all doses, with the 2·2 μg dose showing increased serotype coverage with decreased carrier suppression.

[Articles] Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial

Di |2023-12-05T00:30:04+01:00Dicembre 5th, 2023|Categorie: Coronavirus Lancet|

VAX-24 had a safety profile similar to PCV20 at all doses, with the 2·2 μg dose showing increased serotype coverage with decreased carrier suppression.

[Corrections] Correction to Lancet Infect Dis 2023; published online Nov 20. https://doi.org/10.1016/S1473-3099(23)00500-5

Di |2023-12-05T00:30:01+01:00Dicembre 5th, 2023|Categorie: Coronavirus Lancet|

Webster E, Palanco Lopez P, Kirchhelle C. Shifting targets: typhoid's transformation from an environmental to a vaccine-preventable disease, 1940–2019. Lancet Infect Dis 2023; published online Nov 20. https://doi.org/10.1016/S1473-3099(23)00500-5—In th...

Torna in cima